

12-8089: Anti-Human IL-6 (Sarilumab) DyLight® 488

Clonality :	Monoclonal
Clone Name :	Hu137
Application :	Functional Assay
Reactivity :	Human
Alternative Name :	Interleukin-6, CDF; HGF; HSF; BSF2; BSF-2; IFNB2; IFN-beta-2
Isotype :	Human IgG1k

Description

Expression Host : HEK-293

This non-therapeutic antibody uses the same variable region sequence as the therapeutic antibody Sarilumab. Sarilumab binds to the transmembrane and soluble forms of the IL-6 receptor. This product is for research use only.

IL-6 and its signaling pathway play a part in immune response regulation, inflammation, and hematopoiesis.² Sarilumab is a research-grade recombinant human monoclonal IL-6 receptor antagonist. It specifically binds to both the transmembrane and soluble forms of the IL-6 receptor, thus inhibiting IL-6 α -mediated cis and trans-signaling in a dose-dependent manner.¹ Therapeutic Sarilumab, also known by the trade name Kevzara, is currently used to treat Rheumatoid Arthritis¹, however, as of March 2020, The Feinstein Institute of Northwell Health publicized a study on "a human antibody that may prevent the activity" of IL-6 for the treatment of COVID-19.³ Anti-Human IL-6 (Sarilumab) utilizes the same variable regions from the therapeutic antibody Sarilumab making it ideal for research projects.

Product Info

Amount :	100 μ g
	Concentration : 0.2 mg/ml
Content :	This DyLight® 488 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Storage condition :	This DyLight® 488 conjugate is stable when stored at 2-8°C. Do not freeze.

Application Note

The suggested concentration for Alemtuzumab biosimilar antibody for staining cells in flow cytometry is $\leq 1.0 \mu$ g per 10^6 cells in a volume of 100 μ l. Titration of the reagent is recommended for optimal performance for each application.